Eye cancer is a type of cancer that starts in the eye. It can cause symptoms like vision changes, growths on the eye, or pain. It's important to see a doctor if you notice any unusual changes in your eye.
Every report comes from a Lived member, sent anonymously.
Have you had Brachytherapy for Eye Cancer?
Eye cancer is an uncommon group of cancers that start in or around the eye. Some begin inside the eyeball itself, some start in nearby structures such as the eyelid, tear gland or eye socket, and some reach the eye after spreading from cancer elsewhere in the body. These are different diseases, and the type matters more than the location for understanding treatment and outlook. In adults, the most common cancer that starts inside the eye is melanoma, which grows from the pigment-making cells of the uvea, the middle layer of the eye wall that includes the iris (the colored part), the ciliary body behind it and the choroid at the back. Lymphoma can also start inside the eye. In young children, the main eye cancer is retinoblastoma, a cancer of the retina, the light-sensing layer at the back of the eye. Cancers of the eyelid are usually skin cancers. Cancer that has spread to the eye, most often from the breast or lung, is actually more common than cancer that starts there. Eye cancer matters for two reasons at once: it can threaten sight in the affected eye, and some types, especially melanoma of the choroid or ciliary body, can spread through the bloodstream to other organs, most often the liver.
For eye melanoma, the known risk factors are mostly things a person cannot change. Risk is higher with lighter skin that burns or freckles easily, light-colored eyes, older age and, slightly, in men. Certain pigmented spots in or around the eye, such as a choroidal or iris nevus (a freckle-like mole inside the eye) or nevus of Ota (bluish-gray pigment of the eye and surrounding skin), also raise the risk, which is one reason an eye doctor may photograph and recheck such spots. Rare inherited conditions, including BAP1 tumor predisposition syndrome and atypical mole syndrome, increase risk, and welders appear to be at higher risk. Whether sunlight raises eye melanoma risk is not settled; studies have given mixed results. Retinoblastoma is caused by changes in a gene called RB1. Most cases are not inherited: the change happens by chance, and the cancer usually affects one eye. In the heritable form, the gene change is present from conception, either passed from a parent or arising new. It is more likely when there is a family history, tumors in both eyes or more than one tumor. Children with a family history of retinoblastoma need regular eye exams from early in life unless testing shows they did not inherit the gene change, and genetic counseling can help families understand the risk for siblings and future children.
Eye melanoma often causes no symptoms early on and is sometimes found during a routine eye exam in which drops widen (dilate) the pupil so the doctor can see the back of the eye. When symptoms do occur, they can include blurred or changed vision, new floaters or flashes of light, a dark spot on the iris, or a change in the shape of the pupil. Diagnosis usually rests on a careful examination by an eye specialist, often an ocular oncologist, together with imaging. An ultrasound of the eye measures the tumor's height and width, which drive treatment choices, and photographs, optical coherence tomography (a light-based scan of the retina's layers) or dye tests of the eye's blood vessels help tell melanoma apart from a harmless nevus or other look-alikes. Unlike most cancers, eye melanoma rarely needs a biopsy to be diagnosed, although a sample may be taken to look for genetic changes that help predict the risk of spread. Because melanoma inside the eye tends to spread to the liver, the workup usually includes liver blood tests and imaging of the liver and chest. In children, retinoblastoma is diagnosed by a detailed eye exam, often under anesthesia, along with ultrasound and MRI. A biopsy is usually not needed. Blood testing for the RB1 gene change shows whether the form is heritable, which shapes how closely the other eye and siblings are watched.
Treatment depends on the type of cancer, where it is in the eye, its size and whether it has spread. Care is usually led by specialized eye cancer centers. For eye melanoma, the goals are to control the tumor, keep the eye when possible and preserve as much vision as possible. Radiation is the most common treatment. In plaque brachytherapy, a small disk containing radioactive seeds is stitched to the outside of the eye over the tumor for several days and then removed; it is as effective as removing the eye and controls about 9 in 10 small to medium tumors, although the full effect can take 3 to 6 months to show. Proton beam radiation is an option for tumors a plaque cannot cover well, such as larger ones or those near the optic nerve. Radiation preserves the eye, but it can damage nearby structures and cause cataract, dry eye, glaucoma (high pressure in the eye) or vision loss, sometimes years later. Very small, slow-growing tumors may be watched closely before any treatment. Small tumors can sometimes be treated with laser, and some iris and ciliary body tumors can be cut out. Removing the eye (enucleation) is used when a tumor is too large or vision cannot be saved; an artificial eye matched to the other eye is fitted afterward. When eye melanoma has spread, treatment is harder and is often given in a clinical trial. Tebentafusp (Kimmtrak), an infused immunotherapy that directs the immune system's T cells against melanoma cells, is approved for adults whose cancer has spread or cannot be removed and who carry a specific inherited immune type called HLA-A*02:01, identified by a blood test. In its main trial, people given it lived longer on average than those given other treatments, though tumors shrank in only a minority, and the first doses require hospital monitoring because of a serious immune reaction called cytokine release syndrome. Retinoblastoma treatment aims first to save the child's life, then the eye and vision. Options include laser and freezing treatments for small tumors, chemotherapy given into a vein, directly into the artery supplying the eye or into the eye itself, radiation, and removal of the eye when a tumor is too advanced. Other eye cancers, such as lymphoma, eyelid skin cancers and cancers that have spread to the eye, are treated according to their own type.
The outlook varies widely by type and stage. Most children with retinoblastoma in the United States are cured, with 5-year survival above 95 percent, and the main long-term questions are about vision in the affected eye. For eye melanoma, about 88 percent of people whose cancer is confined to the eye are alive 5 years after diagnosis, compared with about 19 percent when it has already spread to distant organs at diagnosis. These figures come from people diagnosed several years ago and cannot predict any one person's course. After treatment, follow-up continues for many years. For melanoma, that usually means regular eye exams if the eye was kept, plus liver blood tests and imaging, because the cancer can return or appear in the liver long after the eye has been treated. Visits are frequent at first and spread out over time; how often depends on tumor size, location and genetic features. Children with the heritable form of retinoblastoma need eye exams every few months for at least the first two to three years, since new tumors can form, and they carry a higher lifelong risk of other cancers, so long-term survivorship care matters. Daily life depends largely on how much vision the treated eye keeps. Side effects of radiation, such as cataract or dry eye, can often be treated to keep vision as clear as possible. People who have an eye removed are fitted with an artificial eye matched in size and color to the other eye. Worry about recurrence is common, and support from the care team, counselors or other survivors can help.
See an eye doctor for blurred or changed vision, new floaters or flashes, a dark spot on the iris or a change in the shape of the pupil that does not go away, and keep up with recommended rechecks of any known nevus in the eye. If a young child's pupil looks white instead of red, often first noticed in flash photos, contact the child's doctor promptly to arrange an eye exam, since this can be a sign of retinoblastoma and earlier diagnosis can mean less intensive treatment. A newly crossed or wandering eye in a child should also be checked. After treatment for eye melanoma, tell your care team about new symptoms such as vision changes in the treated eye or new pain or swelling around it, rather than waiting for the next scheduled visit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Eye Cancer is like, what's helped you, or ask the community a question.